Acumen Pharmaceuticals Inc ABOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
-
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
-
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
-
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
-
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
Trading Information
- Previous Close Price
- $2.06
- Day Range
- $1.90–2.05
- 52-Week Range
- $1.50–3.60
- Bid/Ask
- $1.97 / $2.03
- Shares Outstanding
- 72.32M
- Market Cap
- $143.19M
- Volume/Avg
- 541,794 / 450,564
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 61
- Website
- https://www.acumenpharm.com
Valuation
|
Metric
|
ABOS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.50 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ABOS
Financial Strength
|
Metric
|
ABOS
|
|---|---|
Quick Ratio | 2.37 |
Current Ratio | 2.47 |
Interest Coverage | −24.52 |
Quick Ratio
ABOS
Profitability
|
Metric
|
ABOS
|
|---|---|
Return on Assets (Normalized) | −69.18% |
Return on Equity (Normalized) | −111.65% |
Return on Invested Capital (Normalized) | −82.53% |
Return on Assets
ABOS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&JSCVRm | LOCK|%<xP^ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|SnRj># | LOCK|#!B#l | $83B | |||
| Moderna Inc
MRNA
| LOCK|VgzC^@ | LOCK|lK | $80B | |||
| argenx SE ADR
ARGX
| LOCK|>B!cDQh | LOCK|CG | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%?yjZR | LOCK|xWL | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|h&DGd$t | LOCK|P!^Jz | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%HX?!>& | LOCK|b&<$% | $28B | |||
| Incyte Corp
INCY
| LOCK|bVm##W | LOCK|%g | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$<#@!@s | LOCK|m$P | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|GQw<yT | LOCK|H%K | $14B |
United States